Welcome to our dedicated page for Milestone Scient SEC filings (Ticker: MLSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Milestone Scientific Inc. (MLSS) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a technology-focused medical research and development company. These SEC filings cover its activities in developing computerized injection technologies and instruments for medical, dental and cosmetic applications, including systems based on its DPS Dynamic Pressure Sensing Technology® platform.
On this page, you can review core periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Milestone Scientific’s dental and medical segments, its computer-controlled injection systems, and related risk factors. These filings also elaborate on topics referenced in company news releases, such as the STA® Single Tooth Anesthesia System, The Wand® STA System, and the CompuFlo® Epidural System, along with information about reimbursement developments and market activities where disclosed.
Current reports on Form 8-K are particularly relevant for tracking material events. Recent 8-K filings for Milestone Scientific include disclosures about leadership changes, compensation arrangements, notices from NYSE American regarding continued listing standards, and matters submitted to stockholders at the annual meeting, such as election of directors, amendments to the Restated Certificate of Incorporation to increase authorized shares of common stock, and ratification of independent auditors.
Stock Titan’s platform provides real-time updates as new Milestone Scientific filings are posted to EDGAR, along with AI-powered summaries that explain the key points of lengthy documents. Investors can quickly locate sections related to topics such as segment discussions, technology descriptions, stockholders’ equity, and governance proposals, as well as monitor any insider-related disclosures that may appear in Forms 3, 4 or 5. This helps users navigate Milestone Scientific’s regulatory history and understand the context behind its stock performance and strategic decisions.
Milestone Scientific Inc. reported it received a NYSE American notice that it is not in compliance with continued listing standards under Sections 1003(a)(ii) and (iii). The company must submit a plan of compliance by November 7, 2025. If the plan is accepted, the listing can continue with periodic reviews.
The Exchange may initiate delisting procedures if the plan is not accepted, if progress is insufficient, or if the company fails to regain compliance by April 8, 2027. Management is pursuing options to address the deficiency and intends to submit a plan by the deadline.
BP4 S.r.l., listed as a Director and 10% Owner, reported insider sales of common stock in MILESTONE SCIENTIFIC INC. (MLSS).
The filing shows two sales: 10,000 shares sold on 10/07/2025 at $0.45 and 30,000 shares sold on 10/08/2025 at $0.465, a total of 40,000 shares. Following the transactions, the reporting person reported beneficial ownership of 9,195,384 shares.
The form is signed by /s/ Dr. Pedro Palau, Liquidator on 10/09/2025. The transactions are reported as direct ownership changes and involve common stock only.
BP4 S.r.l., a director-level reporting person, reported the sale of a total of 19,210 shares of MILESTONE SCIENTIFIC INC. (MLSS) on 10/03/2025 at prices of $0.4491 and $0.45. After these disposals the reporting person beneficially owned 9,235,384 shares. No derivative transactions are reported and the Form 4 is signed by the liquidator on 10/08/2025.
BP4 S.r.l., listed as a director of Milestone Scientific Inc. (MLSS), reported a sale of 10,000 shares of the issuer's common stock on 09/11/2025 at a price of $0.594 per share. After the transaction the filing indicates beneficial ownership of 9,256,972 shares, held indirectly. The Form 4 was signed by Dr. Pedro Palau, Liquidator and filed on 09/15/2025. The filing shows a single non-derivative disposition and does not disclose any derivative transactions or a Rule 10b5-1 plan.
Form 144 notice filed regarding proposed sale of 400,000 shares of Milestone Scientific, Inc. common stock, with an aggregate market value of $236,000, scheduled approximately for 09/10/2025 on the NYSE. The filing lists 78,559,147 shares outstanding for the class. The securities to be sold were originally acquired in a private placement on 05/14/2014 (2,000,000 shares) from Milestone Scientific, paid in cash. The form also reports a recent sale by BP4 Srl of 375,485 shares on 06/02/2025 for $301,082. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Milestone Scientific (NYSE:MLSS) filed a routine Form 4 reporting two small open-market sales by 10 % owner BP4 S.r.l. The insider sold 10,056 shares on 06/16/2025 at $0.8951 and 1,693 shares on 06/18/2025 at $0.88, totaling 11,749 shares (≈ $10.5 K).
Following the transactions, BP4 S.r.l.’s beneficial ownership declined by less than 0.2 % to 9,447,183 common shares. No derivative trades or additional material changes were disclosed.